FLT3 ligand plasma levels in acute myeloid leukemia, Haematologica ,
URL : https://hal.archives-ouvertes.fr/inserm-01993986
The Cytokine Flt3-ligand in normal and malignant hematopoiesis, Int. J. Mol. Sci, vol.18, p.6 ,
Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand, Blood, vol.103, issue.10, pp.3860-3868, 2004. ,
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells, Leukemia, vol.10, issue.4, pp.588-599, 1996. ,
Flt3 ligand induces tumor regression and antitumor immune responses in vivo, Nat. Med, vol.3, issue.6, pp.625-631, 1997. ,
FLT3-ligand administration inhibits liver metastases: role of NK cells, J. Immunol. Baltim. Md, issue.11, pp.6164-6170, 1950. ,
In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice, Blood, vol.97, issue.5, pp.1474-1482, 2001. ,
Antileukemic activity of Flt3 ligand in murine leukemia, Cancer Res, vol.60, issue.7, pp.1895-1900, 2000. ,
Microchimerism donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus, J. Immunol. Baltim. Md, vol.165, issue.1, pp.226-237, 1950. ,
FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease, Transplantation, vol.75, issue.7, pp.933-940, 2003. ,
Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease, Blood, vol.99, issue.5, pp.1825-1832, 2002. ,
Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD In, %2C+Bunworasate+U%2C+et+al.+International%2C+Multicenter +Standardization+of+Acute+Graft-versus-Host+Disease+Clinical+Data +Collection%3A >, 2019. ,
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.11, issue.12, pp.945-956, 2005. ,
Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.7, issue.4, pp.197-207, 2001. ,
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.11, issue.1, pp.23-34, 2005. ,